Brief: Avrobio Announces Positive Data From Phase 1/2 Clinical Trial Of Investigational Gene Therapy

Tectonic Therapeutic

18/05/2023 12:02

May 18 (Reuters) - AVROBIO Inc  AVRO.O :
    * AVROBIO ANNOUNCES POSITIVE DATA FROM PHASE 1/2 CLINICAL
TRIAL OF
INVESTIGATIONAL GENE THERAPY FOR CYSTINOSIS AT THE ASGCT 26TH
ANNUAL MEETING
    * AVROBIO INC - ALL PATIENTS REMAIN OFF ORAL CYSTEAMINE UP
TO 36
MONTHS POST GENE THERAPY
    * AVROBIO INC - SUSTAINED ENGRAFTMENT AND DURABLE REDUCTION
IN
LEUKOCYTE CYSTINE LEVELS ACROSS ALL PATIENTS
    * AVROBIO INC - SAFETY AND TOLERABILITY PROFILE REMAINS
STRONG

Source text for Eikon:  ID:nBw5JYbcra 
Further company coverage:  AVRO.O